May. 08, 2024
DB-OTO Gene Therapy Delivers Dramatic Improvements in Hearing Within 24 Weeks
TARRYTOWN, NEW YORK — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed in a second child (dosed at 4 years of age) at a 6-week assessment. Both children were born with profound